PubRank

Bernd Kuhn

Author PubWeight™ 38.40‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 A medicinal chemist's guide to molecular interactions. J Med Chem 2010 3.39
2 Fluorine in medicinal chemistry. Chembiochem 2004 3.25
3 Small molecule conformational preferences derived from crystal structure data. A medicinal chemistry focused analysis. J Chem Inf Model 2008 2.04
4 Radially expanding transglial calcium waves in the intact cerebellum. Proc Natl Acad Sci U S A 2009 1.58
5 Systematic investigation of halogen bonding in protein-ligand interactions. Angew Chem Int Ed Engl 2011 1.54
6 ANNINE-6plus, a voltage-sensitive dye with good solubility, strong membrane binding and high sensitivity. Eur Biophys J 2007 1.17
7 A novel partial agonist of peroxisome proliferator-activated receptor-gamma (PPARgamma) recruits PPARgamma-coactivator-1alpha, prevents triglyceride accumulation, and potentiates insulin signaling in vitro. Mol Endocrinol 2005 1.11
8 Fluorescence-based monitoring of in vivo neural activity using a circuit-tracing pseudorabies virus. PLoS One 2009 1.06
9 Design of novel aminopyrrolidine factor Xa inhibitors from a screening hit. Eur J Med Chem 2009 0.94
10 Aleglitazar, a new, potent, and balanced dual PPARalpha/gamma agonist for the treatment of type II diabetes. Bioorg Med Chem Lett 2009 0.92
11 Theoretical and experimental studies of biotin analogues that bind almost as tightly to streptavidin as biotin. J Org Chem 2002 0.90
12 1,3-disubstituted 4-aminopiperidines as useful tools in the optimization of the 2-aminobenzo[a]quinolizine dipeptidyl peptidase IV inhibitors. Bioorg Med Chem Lett 2007 0.89
13 Recent developments in the understanding of astrocyte function in the cerebellum in vivo. Cerebellum 2010 0.89
14 Calcium imaging of neuronal circuits in vivo using a circuit-tracing pseudorabies virus. Cold Spring Harb Protoc 2010 0.87
15 Comparative molecular profiling of the PPARα/γ activator aleglitazar: PPAR selectivity, activity and interaction with cofactors. ChemMedChem 2012 0.87
16 Efficient stacking on protein amide fragments. ChemMedChem 2013 0.87
17 Discovery of novel and orally active FXR agonists for the potential treatment of dyslipidemia & diabetes. Bioorg Med Chem Lett 2010 0.86
18 Discovery of carmegliptin: a potent and long-acting dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. Bioorg Med Chem Lett 2009 0.86
19 Aminomethylpyrimidines as novel DPP-IV inhibitors: a 10(5)-fold activity increase by optimization of aromatic substituents. Bioorg Med Chem Lett 2004 0.83
20 Design and biological evaluation of novel, balanced dual PPARalpha/gamma agonists. ChemMedChem 2009 0.83
21 Identification of an N-oxide pyridine GW4064 analog as a potent FXR agonist. Bioorg Med Chem Lett 2009 0.82
22 Injection of recombinant adenovirus for delivery of genetically encoded calcium indicators into astrocytes of the cerebellar cortex. Cold Spring Harb Protoc 2011 0.82
23 Halogen bonding at the active sites of human cathepsin L and MEK1 kinase: efficient interactions in different environments. ChemMedChem 2011 0.82
24 Synthesis and biological evaluation of fenobam analogs as mGlu5 receptor antagonists. Bioorg Med Chem Lett 2006 0.81
25 Optical pH detection within a protein crystal. J Phys Chem B 2012 0.81
26 Degradation of aromatics and chloroaromatics by Pseudomonas sp. strain B13: purification and characterization of 3-oxoadipate:succinyl-coenzyme A (CoA) transferase and 3-oxoadipyl-CoA thiolase. J Bacteriol 2002 0.81
27 A new DNA gyrase inhibitor subclass of the cyclothialidine family based on a bicyclic dilactam-lactone scaffold. Synthesis and antibacterial properties. J Med Chem 2011 0.80
28 Discovery of a factor Xa inhibitor (3R,4R)-1-(2,2-difluoro-ethyl)-pyrrolidine-3,4-dicarboxylic acid 3-[(5-chloro-pyridin-2-yl)-amide] 4-[[2-fluoro-4-(2-oxo-2H-pyridin-1-yl)-phenyl]-amide] as a clinical candidate. Bioorg Med Chem Lett 2010 0.80
29 Aryl- and heteroaryl-substituted aminobenzo[a]quinolizines as dipeptidyl peptidase IV inhibitors. Bioorg Med Chem Lett 2009 0.80
30 New Insights on the mechanism of PPAR-targeted drugs. ChemMedChem 2010 0.80
31 Allosteric FBPase inhibitors gain 10(5) times in potency when simultaneously binding two neighboring AMP sites. Bioorg Med Chem Lett 2008 0.79
32 Mutagenesis and molecular modeling of the orthosteric binding site of the mGlu2 receptor determining interactions of the group II receptor antagonist (3)H-HYDIA. ChemMedChem 2009 0.77
33 Synthesis and evaluation of anilinohexafluoroisopropanols as activators/modulators of LXRalpha and beta. Bioorg Med Chem Lett 2006 0.77
34 Preferential loading of bergmann glia with synthetic acetoxymethyl calcium dyes. Cold Spring Harb Protoc 2011 0.76
35 Orally active aminopyridines as inhibitors of tetrameric fructose-1,6-bisphosphatase. Bioorg Med Chem Lett 2011 0.76
36 Sulfonylureido thiazoles as fructose-1,6-bisphosphatase inhibitors for the treatment of type-2 diabetes. Bioorg Med Chem Lett 2009 0.76
37 Molecular layer interneurons relay cerebellar cortical activity to Bergmann glial cells. J Neurosci 2007 0.75
38 Cerebellar craniotomy for in vivo calcium imaging of astrocytes. Cold Spring Harb Protoc 2011 0.75
39 Rhenium and technetium complexes with tridentate N-[(N'',N''-dialkylamino)(thiocarbonyl)]-N'-substituted benzamidine ligands. Inorg Chem 2008 0.75
40 Synthesis of annulated pyridines as inhibitors of aldosterone synthase (CYP11B2). Org Biomol Chem 2016 0.75